

Supplementary Table I. Tender (TJC) and swollen (SJC) joint counts in patients with or without DIP joint disease, categorised according to MDA status.

	MDA ⁺	MDA ⁻
TJC DIP ⁺	0 (0-3)	4 (0-33)
TJC DIP ⁻	0 (0-6)	2 (0-20)
SJC DIP ⁺	0 (0-4)	2.5 (0-14)
SJC DIP ⁻	0 (0-2)	1 (0-16)


All data were given as median (first-third percentiles).

DIP: distal interphalangeal; MDA: minimal disease activity; TJC: tender joint counts; SJC: swollen joint counts.

Supplementary Table II. The disease characteristics of patients with MDA⁻ vs. MDA⁺.

	MDA ⁻	MDA ⁺	<i>p</i> -value
TJC	1 (0-5)	0 (0-1)	<0.001
TJC (≤1)	130 (88.4)	53 (31.2)	<0.001
SJC	1 (0-3)	0 (0-0)	<0.001
SJC (≤1)	140 (95.2)	91 (53.5)	<0.001
TEP	0 (0-0)	0 (0-0)	0.011
TEP (≤1)	146 (99.3)	159 (93.5)	0.007
BSA	5 (1-15)	1 (0-5)	<0.001
BSA (≤3)	119 (81)	87 (51.2)	<0.001
PtGA	50 (30-60)	20 (10-20)	<0.001
PtGA (≤20)	108 (73.5)	22 (12.9)	<0.001
Pain VAS	50 (30-70)	10 (3-20)	<0.001
Pain VAS (≤15)	83 (56.5)	14 (8.2)	<0.001
HAQ	0.65 (0.3-1)	0.10 (0-0.3)	<0.001
HAQ (≤0.5)	130 (88.4)	62 (36.5)	<0.001
BASDAI	41 (25-55)	10 (2-26)	<0.001
BASFI	29 (17-45)	9 (0-15)	<0.001
PGA	35 (20-50)	10 (10-20)	<0.001
CRP (mg/ dl)	6.3 (2.35-17)	3 (1.91-4.96)	<0.001
ESR (mm/hour)	21 (10-37)	12 (6-25)	<0.001
<i>Comorbidities</i>			
Diabetes Mellitus	27/170 (15.8)	20/147 (13.7)	0.636
Hypertension	40/170 (23.4)	26/147 (17.8)	0.267
Hyperlipidaemia	38/170 (22.2)	26/147 (17.8)	0.400
Coronary artery disease	6/170 (3.5)	6/147 (4.1)	0.778
Cerebrovascular event	9/170 (5.3)	0/147 (0)	0.004
Depression	22/170 (12.9)	11/147 (7.5)	0.142
Cancer	4/170 (2.3)	3/147 (2.1)	0.864
Liver disease	10/170 (5.8)	5/147 (3.4)	0.428

All data were given as median (first-third percentiles). TJC: tender joint count; TEP: tender enthesal point; BSA: body surface area; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; HAQ: Health Assessment Questionnaire; PtGA: Patient Global Assessment; PGA: Physician Global Assessment; VAS: Visual analogue scale; CRP: C reactive protein; ESR: eritrosit sedimentation rate; MDA: minimal disease activity.

**Supplementary Fig. 1.**

The rate of achievement MDA according to the last treatments.

(Others: patients on conventional DMARD therapies; biologics: anti-TNF and secukinumab).